Assystem: Invest Securities on hold, same TP
(CercleFinance.com) - Invest Securities confirms its 'neutral' rating on Assystem shares, with an unchanged target price of E37, even though the analyst points to a medium- to long-term revival in the nuclear sector.
He nevertheless points to the stock's "limited potential" and "weak" short-term momentum.
Q4 sales finally came in slightly above the expectations lowered at the end of October after the profit warning.
However, the slowdown in Nuclear activities in France confirms that short-term momentum will be limited, with organic growth likely to remain below +10% for 2/3 years, the analyst says.
The main question mark in the short term is Expleo, whose sale is likely to be postponed and the price limited to a minimum.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
He nevertheless points to the stock's "limited potential" and "weak" short-term momentum.
Q4 sales finally came in slightly above the expectations lowered at the end of October after the profit warning.
However, the slowdown in Nuclear activities in France confirms that short-term momentum will be limited, with organic growth likely to remain below +10% for 2/3 years, the analyst says.
The main question mark in the short term is Expleo, whose sale is likely to be postponed and the price limited to a minimum.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.